New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTesofensine vs Ipamorelin

Tesofensine vs Ipamorelin

Side-by-side comparison of key properties, dosing, and research.

Fat Loss & Metabolic
Tesofensine
Growth Hormone Peptides
Ipamorelin
Summary
Tesofensine is a triple monoamine reuptake inhibitor (TMRI) that blocks reuptake of serotonin, dopamine, and norepinephrine. Originally developed for Alzheimer's and Parkinson's disease, it was repurposed as a potent weight loss agent after clinical trials demonstrated substantial fat loss via appetite suppression and increased energy expenditure.
Ipamorelin is a selective GHRP (growth hormone releasing peptide) and one of the cleanest GH secretagogues available. It selectively stimulates GH release without significantly raising cortisol, prolactin, or appetite — making it ideal for long-term use and anti-aging protocols.
Half-Life
8-10 days (exceptionally long; accumulates over weeks)
2 hours
Admin Route
Oral
SubQ
Research
Typical Dose
0.25-0.5 mg per day
100–300 mcg
Frequency
Once daily
Once to twice daily
Key Benefits
  • Potent appetite suppression via triple monoamine reuptake inhibition
  • Significant weight loss (8-12% body weight in phase II trials at 0.5 mg)
  • Increases basal metabolic rate and energy expenditure
  • Reduces fat mass preferentially over lean mass
  • Potential cognitive benefit via dopaminergic and noradrenergic enhancement
  • Longer half-life than sibutramine allows once-daily dosing
  • Increases lean muscle mass
  • Enhances fat loss
  • Improves recovery time
  • Strengthens bones and joints
  • Better sleep quality and REM sleep
  • Enhanced skin elasticity
  • Minimal impact on hunger or cortisol
  • No cortisol or prolactin spike
  • Clean GH release suitable for long-term protocols
Side Effects
  • Elevated heart rate and blood pressure (sympathomimetic)
  • Dry mouth
  • Insomnia and sleep disturbances
  • Nausea
  • +4 more
  • Injection site irritation
  • Temporary water retention (mild)
  • Possible hunger increase (milder than GHRP-6)
  • Numbness or tingling in extremities (rare)
Stacks With